Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure.

Abstract

Andes virus (ANDV) and ANDV-like viruses are responsible for most hantavirus pulmonary syndrome (HPS) cases in South America. Recent studies in Chile indicate that passive transfer of convalescent human plasma shows promise as a possible treatment for HPS. Unfortunately, availability of convalescent plasma from survivors of this lethal disease is very limited. We are interested in exploring the concept of using DNA vaccine technology to produce antiviral biologics, including polyclonal neutralizing antibodies for use in humans. Geese produce IgY and an alternatively spliced form, IgYΔFc, that can be purified at high concentrations from egg yolks. IgY lacks the properties of mammalian Fc that make antibodies produced in horses, sheep, and rabbits reactogenic in humans. Geese were vaccinated with an ANDV DNA vaccine encoding the virus envelope glycoproteins. All geese developed high-titer neutralizing antibodies after the second vaccination, and maintained high-levels of neutralizing antibodies as measured by a pseudovirion neutralization assay (PsVNA) for over 1 year. A booster vaccination resulted in extraordinarily high levels of neutralizing antibodies (i.e., PsVNA80 titers >100,000). Analysis of IgY and IgYΔFc by epitope mapping show these antibodies to be highly reactive to specific amino acid sequences of ANDV envelope glycoproteins. We examined the protective efficacy of the goose-derived antibody in the hamster model of lethal HPS. α-ANDV immune sera, or IgY/IgYΔFc purified from eggs, were passively transferred to hamsters subcutaneously starting 5 days after an IM challenge with ANDV (25 LD50). Both immune sera, and egg-derived purified IgY/IgYΔFc, protected 8 of 8 and 7 of 8 hamsters, respectively. In contrast, all hamsters receiving IgY/IgYΔFc purified from normal geese (n=8), or no-treatment (n=8), developed lethal HPS. These findings demonstrate that the DNA vaccine/goose platform can be used to produce a candidate antiviral biological product capable of preventing a lethal disease when administered post-exposure.

• Authors: Nicole Haese, Rebecca L Brocato, Thomas Henderson, Matthew L Nilles, Steve A Kwilas, Matthew D Josleyn, Christopher D Hammerbeck, James Schiltz, Michael Royals, John Ballantyne, Jay W Hooper, David S Bradley
• Journal: PLoS neglected tropical diseases (PLoS Negl Trop Dis) Vol. 9 Issue 6 Pg. e0003803 ( 2015) ISSN: 1935-2735 [Electronic] United States
• PMID: 26046641 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Antibodies, Neutralizing
• IgY
• Immunoglobulins
• Rosaniline Dyes
• Vaccines, DNA
• Coomassie blue

Topics

• Animals
• Antibodies, Neutralizing (immunology, therapeutic use)
• Cricetinae
• Geese (immunology)
• Hantavirus Pulmonary Syndrome (prevention & control)
• Immunoglobulins (biosynthesis, immunology, therapeutic use)
• Mesocricetus
• Post-Exposure Prophylaxis (methods)
• Rosaniline Dyes
• Vaccines, DNA (immunology)